Tuberous Sclerosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

3 events
Jan 2023Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex

Katarzyna Kotulska — PHASE3

TrialRECRUITING
Jan 2022Gait in Rare Diseases

Universiteit Antwerpen — NA

TrialACTIVE NOT RECRUITING
Jan 2000Study of Skin Tumors in Tuberous Sclerosis

National Heart, Lung, and Blood Institute (NHLBI) — NA

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

1

Open now

2

Travel grants

Travel Grants2

Afinitor Everolimus Copay Assistance Program

OpenContact for detailsApply ↗

Tuberous Sclerosis Association Support Fund

Tuberous Sclerosis Association

Contact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Crestor

(rosuvastatin)Orphan drugstandard

iPR Pharmaceuticals, Inc.

12.1 Mechanism of Action CRESTOR is an inhibitor of HMG‑CoA reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

3 active trials
1Phase 3
2N/A
3Total recruiting
Search clinical trials for Tuberous Sclerosis

Recent News & Research

No recent news articles indexed yet for Tuberous Sclerosis.
Search PubMed for Tuberous Sclerosis

Browse all Tuberous Sclerosis news →

Specialist Network

Top 5 by expertise

View all Tuberous Sclerosis specialists →

Quick Actions